Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

Stock Information for Verastem Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Verastem Inc.

Verastem Oncology to Present at the Jefferies Global Healthcare Conference
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
FDA Approves the AVMAPKI(TM) FAKZYNJA(TM) Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer
Verastem Oncology to Present at Upcoming Investor Conferences
Verastem Oncology Announces $75 million Private Placement
Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.